Cannabinoids in experimental stroke: a systematic review and meta-analysis.

“Cannabinoids (CBs) show promise as neuroprotectants with some agents already licensed in humans for other conditions. We systematically reviewed CBs in preclinical stroke to guide further experimental protocols…

Cannabinoids reduced infarct volume in transient and permanent ischemia and in all subclasses: endocannabinoids, CB1/CB2 ligands, CB2 ligands, cannabidiol, Δ9-tetrahydrocannabinol, and HU-211. Early and late neuroscores significantly improved with CB use…

Overall, CBs significantly reduced infarct volume and improve functional outcome in experimental stroke.”

 http://www.ncbi.nlm.nih.gov/pubmed/25492113

http://www.thctotalhealthcare.com/category/stroke-2/

Facebook Twitter Pinterest Stumbleupon Tumblr Posterous

Leave a Reply

Your email address will not be published. Required fields are marked *